Credit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BofA/Merrill Lynch Starts Aimmune Therapeutics (AIMT) at Buy
August 31, 2015 7:43 AM EDTBofA/Merrill Lynch initiated coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Buy rating and a price target of $36.00.
For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.
Shares of Aimmune Therapeutics closed at $21.11 yesterday.
... MorePiper Jaffray Starts Aimmune Therapeutics (AIMT) at Overweight
August 31, 2015 6:27 AM EDTPiper Jaffray initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Overweight rating and a price target of $35.00, leading data in peanut allergy.
Analyst Charles Duncan commented, "Aimmune is leveraging its broadly applicable oral immunotherapy (OIT) platform to develop proprietary products aimed at protecting patients... More
